Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Osimertinib (Primary) ; Pamvatamig (Primary)
- Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Merus
- 22 Aug 2024 Planned number of patients changed from 600 to 576.
- 22 Aug 2024 Planned End Date changed from 1 Apr 2025 to 1 Mar 2027.
- 22 Aug 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Mar 2026.